ArticleFamilial cancer2025
Reliability and validity of the multidimensional impact of cancer risk assessment (MICRA) questionnaire: Japanese version.
Article in Familial cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Japanese version of MICRA: introduction of the Shizuoka Cancer Center version.Familial cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to develop and validate a Multidimensional Impact of Cancer Risk Assessment questionnaire-Japanese version (MICRA-J) as an assessment of the psychosocial impact of genetic testing. The MICRA was translated into Japanese using standardized translation procedures. The reliability and validity of the MICRA-J were evaluated in individuals who underwent BRCA1/2 testing for hereditary breast and ovarian cancer diagnosis. The 72 respondents included patients with BRCA1/2 pathogenic variants (n = 20), BRCA1/2 negative (n = 35), variants of uncertain significance (VUS, n = 6), participants with cascade testing positive (n = 7), and participants with cascade testing negative (n = 4). Total MICRA-J scores were positively correlated with Hospital Anxiety and Depression Scale (HADS) scores and negatively correlated with the 36-item short-form version 2 acute (SF-36v2 acute) scores (P < 0.05). The MICRA-J showed good internal consistency coefficients (α > 0.70). Furthermore, high test-retest correlations were obtained when the 64 participants responded to the MICRA-J twice within a short period (Pearson's correlation coefficient = 0.85). The MICRA-J Total score was higher in the groups with BRCA1/2 pathogenic variant carriers than in the BRCA1/2 negative group, whereas the HADS and SF36v2 acute did not differ significantly. These results suggest that the reliability and validity of the MICRA-J have been established. The MICRA-J, similar to the MICRA in other languages, is considered a useful tool to specifically measure the psychosocial impact of genetic testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.